US heart valve firm expands S'pore plant
[SINGAPORE] A global specialist in heart valves and haemodynamic monitoring has announced the expansion of its heart valve manufacturing facility here, giving a fillip to Singapore's medical technology industry.
Edwards Lifesciences, citing growing worldwide demand for tissue heart valves, will more than double the size of its current facility in Changi North to about 24,000 square metres. New offices, laboratories, a large clean room and training facilities will be added to the premises.
The Business Times understands that the California-based company had pumped about $55 million into the expansion. With this, Edwards has invested about $95 million in Singapore since 2005.
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
New Articles
Singapore top recipient of Q1 cross-border investments in Apac: Knight Frank
Dasin Retail Trust’s trustee-manager chairman, directors deny allegations of misconduct
Keppel Infrastructure Trust posts 29.1% lower Q1 distributable income
Bitcoin faces worst month since FTX crash with ETF demand cooling
AIA launches wealth centre targeting high-net-worth clients
Prudential’s Q1 new business profit down 2% at S$743 million